Skip to main content
. 2022 Sep 9;12:930024. doi: 10.3389/fonc.2022.930024

Figure 1.

Figure 1

Expression and survival of SNORA38 signature in breast cancer. (A) SNORA38 expressed higher in breast cancer tissues than in normal tissues in TCGA (P < 0.05). (B) High SNORA38 expression was relevant to a shorter OS in all BC patients in Kaplan–Meier plotter (P = 0.030). (C) High SNORA38 expression was relevant to a shorter OS in luminal A patients in Kaplan–Meier plotter (P = 0.025). (D) High SNORA38 expression did not show any association with a shorter OS in luminal B patients in Kaplan–Meier plotter (P = 0.973). (E) High SNORA38 expression did not show any association with a shorter OS in Her-2 type patients in Kaplan–Meier plotter (P = 0.501). (F) High SNORA38 expression did not show any association with a shorter OS in basal-like type patients in Kaplan–Meier plotter (P = 0.225).